Overview
Miltefosine is a broad spectrum antimicrobial, anti-leishmanial, phospholipid drug that was originally developed in the 1980s as an anti-cancer agent. It is currently the only recognized oral agent used to treat visceral, cutaneous, and mucosal forms of leishmaniasis, a neglected tropical disease. It can be administered topically or orally and is only indicated in patients aged 12 years or older. The CDC has also recommended it as a first line treatment for free-living amebae (FLA) infections such as primary amebic meningoencephalitis and granulomatous amebic encephalitis.
Indication
For the treatment of mucosal (caused by Leishmania braziliensis), cutaneous (caused by L. braziliensis, L. guyanensis, and L. panamensis), and visceral leishmaniasis (caused by L. donovani). In comparing Leishmania drug susceptibility, it has been found that L. donovani is the most susceptible to miltefosine while L. major is the least susceptible. Off-label use includes treatment of free-living amebae (FLA) infections (unlabeled use; CDC, 2013).
Associated Conditions
- Cutaneous Leishmaniasis
- Mucocutaneous Leishmaniasis
- Specific infections by free-living amoebae
- Visceral Leishmaniasis
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
|---|---|---|---|---|---|
2024/08/13 | Phase 2 | Recruiting | Fundacion Nacional de Dermatologia | ||
2024/07/23 | N/A | Recruiting | Institute of Tropical Medicine, Belgium | ||
2024/02/09 | Early Phase 1 | Recruiting | |||
2023/09/15 | Phase 2 | Recruiting | University of Brasilia | ||
2021/03/16 | Phase 3 | Recruiting | Fundacion Nacional de Dermatologia | ||
2020/08/17 | Phase 3 | Completed | Drugs for Neglected Diseases | ||
2019/07/02 | N/A | Completed | Institute of Tropical Medicine, Belgium | ||
2019/02/04 | Phase 2 | Completed | Fundacion Nacional de Dermatologia | ||
2018/02/26 | Phase 2 | Completed | |||
2018/01/17 | Phase 2 | UNKNOWN | Drugs for Neglected Diseases |
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
|---|---|---|---|---|---|
| Profounda, Inc. | 69051-300 | ORAL | 50 mg in 1 1 | 8/11/2023 |
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
|---|---|---|---|
| No EMA approvals found for this drug. | |||
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No HSA approvals found for this drug. | |||||
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
|---|---|---|---|---|---|
| No NMPA approvals found for this drug. | |||||
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
|---|---|---|---|---|---|
| No PPB approvals found for this drug. | |||||
TGA Drug Approvals
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
|---|---|---|---|---|---|
| No TGA approvals found for this drug. | |||||
Help Us Improve
Your feedback helps us provide better drug information and insights.